Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Correction

Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options

Authors: Peter F. McAnena, Andrew McGuire, A. Ramli, C. Curran, C. Malone, R. McLaughlin, K. Barry, James A. L. Brown, M. J. Kerin

Published in: BMC Cancer | Issue 1/2018

Login to get access

Excerpt

It has been highlighted that the original manuscript [1] contains a typesetting error regarding the authorship and did not mention the name of Andrew McGuire. The authorship was incorrectly captured as Peter F. McAnena1, James AL Brown1, A. Ramli1, C. Curran1, C. Malone2, R. McLaughlin2, K. Barry2, Brown JAL1* and M. J. Kerin1 in the original article. The correct authorship is: Peter F. McAnena1, Andrew McGuire1, A. Ramli1, C. Curran1, C. Malone2, R. McLaughlin2, K. Barry2, James A.L. Brown1* and M. J. Kerin1 . The original article has been updated. …
Literature
1.
Metadata
Title
Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options
Authors
Peter F. McAnena
Andrew McGuire
A. Ramli
C. Curran
C. Malone
R. McLaughlin
K. Barry
James A. L. Brown
M. J. Kerin
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4174-3

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Study protocol

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

Research article

Lesions of “uncertain malignant potential” in the breast (B3) identified with mammography screening

Review

Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance

Research article

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors

Study protocol

Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial

Research article

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits